1641. Characterisation of innate lymphoid cell subsets infiltrating colorectal carcinoma.
作者: Paolo Carrega.;Paola Orecchia.;Linda Quatrini.;Nicola Tumino.;Roberta Venè.;Roberto Benelli.;Alessandro Poggi.;Stefano Scabini.;Maria Cristina Mingari.;Lorenzo Moretta.;Paola Vacca.
来源: Gut. 2020年69卷12期2261-2263页 1642. Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial.
作者: Arne G C Bleijenberg.;Monique E van Leerdam.;Marloes Bargeman.;Jan Jacob Koornstra.;Yasmijn J van Herwaarden.;Manon Cw Spaander.;Silvia Sanduleanu.;Barbara A J Bastiaansen.;Erik J Schoon.;Niels van Lelyveld.;Evelien Dekker.;Joep E G IJspeert.
来源: Gut. 2020年69卷12期2150-2158页
Serrated polyps (SPs) are an important cause of postcolonoscopy colorectal cancers (PCCRCs), which is likely the result of suboptimal SP detection during colonoscopy. We assessed the long-term effect of a simple educational intervention focusing on optimising SP detection.
1644. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
作者: Debora Salerno.;Letizia Chiodo.;Vincenzo Alfano.;Oceane Floriot.;Grazia Cottone.;Alexia Paturel.;Matteo Pallocca.;Marie-Laure Plissonnier.;Safaa Jeddari.;Laura Belloni.;Mirjam Zeisel.;Massimo Levrero.;Francesca Guerrieri.
来源: Gut. 2020年69卷11期2016-2024页
The HBV HBx regulatory protein is required for transcription from the covalently closed circular DNA (cccDNA) minichromosome and affects the epigenetic control of both viral and host cellular chromatin.
1645. Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
作者: Arnaud Carpentier.;Julie Sheldon.;Florian W R Vondran.;Richard Jp Brown.;Thomas Pietschmann.
来源: Gut. 2020年69卷9期1659-1666页
Human stem cell-derived hepatocyte-like cells (HLCs) have shown high potential as authentic model for dissection of the HCV life cycle and virus-induced pathogenesis. However, modest HCV replication, possibly due to robust innate immune responses, limits their broader use. To overcome these limitations and to dissect the mechanisms responsible for control of HCV, we analysed expression of key components of the interferon (IFN) system in HLCs, assessed permissiveness for different HCV strains and blocked innate immune signalling by pharmacological intervention.
1646. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.
作者: Dhiraj Tripathi.;Adrian J Stanley.;Peter C Hayes.;Simon Travis.;Matthew J Armstrong.;Emmanuel A Tsochatzis.;Ian A Rowe.;Nicholas Roslund.;Hamish Ireland.;Mandy Lomax.;Joanne A Leithead.;Homoyon Mehrzad.;Richard J Aspinall.;Joanne McDonagh.;David Patch.
来源: Gut. 2020年69卷7期1173-1192页
These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the Liver Section of the BSG. The guidelines are new and have been produced in collaboration with the British Society of Interventional Radiology (BSIR) and British Association of the Study of the Liver (BASL). The guidelines development group comprises elected members of the BSG Liver Section, representation from BASL, a nursing representative and two patient representatives. The quality of evidence and grading of recommendations was appraised using the GRADE system. These guidelines are aimed at healthcare professionals considering referring a patient for a TIPSS. They comprise the following subheadings: indications; patient selection; procedural details; complications; and research agenda. They are not designed to address: the management of the underlying liver disease; the role of TIPSS in children; or complex technical and procedural aspects of TIPSS.
1647. Big data in IBD: big progress for clinical practice.
作者: Nasim Sadat Seyed Tabib.;Matthew Madgwick.;Padhmanand Sudhakar.;Bram Verstockt.;Tamas Korcsmaros.;Séverine Vermeire.
来源: Gut. 2020年69卷8期1520-1532页
IBD is a complex multifactorial inflammatory disease of the gut driven by extrinsic and intrinsic factors, including host genetics, the immune system, environmental factors and the gut microbiome. Technological advancements such as next-generation sequencing, high-throughput omics data generation and molecular networks have catalysed IBD research. The advent of artificial intelligence, in particular, machine learning, and systems biology has opened the avenue for the efficient integration and interpretation of big datasets for discovering clinically translatable knowledge. In this narrative review, we discuss how big data integration and machine learning have been applied to translational IBD research. Approaches such as machine learning may enable patient stratification, prediction of disease progression and therapy responses for fine-tuning treatment options with positive impacts on cost, health and safety. We also outline the challenges and opportunities presented by machine learning and big data in clinical IBD research.
1648. Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis.
作者: Dakota N Jackson.;Marina Panopoulos.;William L Neumann.;Kevin Turner.;Brandi L Cantarel.;LuAnn Thompson-Snipes.;Themistocles Dassopoulos.;Linda A Feagins.;Rhonda F Souza.;Jason C Mills.;Richard S Blumberg.;K Venuprasad.;Winston E Thompson.;Arianne L Theiss.
来源: Gut. 2020年69卷11期1928-1938页
Although perturbations in mitochondrial function and structure have been described in the intestinal epithelium of Crohn's disease and ulcerative colitis patients, the role of epithelial mitochondrial stress in the pathophysiology of inflammatory bowel diseases (IBD) is not well elucidated. Prohibitin 1 (PHB1), a major component protein of the inner mitochondrial membrane crucial for optimal respiratory chain assembly and function, is decreased during IBD.
1649. Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
作者: Sevana Khaloian.;Eva Rath.;Nassim Hammoudi.;Elisabeth Gleisinger.;Andreas Blutke.;Pieter Giesbertz.;Emanuel Berger.;Amira Metwaly.;Nadine Waldschmitt.;Matthieu Allez.;Dirk Haller.
来源: Gut. 2020年69卷11期1939-1951页
Reduced Paneth cell (PC) numbers are observed in inflammatory bowel diseases and impaired PC function contributes to the ileal pathogenesis of Crohn's disease (CD). PCs reside in proximity to Lgr5+ intestinal stem cells (ISC) and mitochondria are critical for ISC-renewal and differentiation. Here, we characterise ISC and PC appearance under inflammatory conditions and describe the role of mitochondrial function for ISC niche-maintenance.
1651. High risk of microscopic colitis after Campylobacter concisus infection: population-based cohort study.
Microscopic colitis (MC) encompasses the two histopathological distinct entities of collagenous colitis (CC) and lymphocytic colitis (LC). In this Danish population-based cohort study, we examined the risk of MC following stool culture with Campylobacter concisus, C. jejuni, non-typhoidal Salmonella or a culture-negative stool test.
1653. Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice.
作者: Sei Higuchi.;Tiara R Ahmad.;Donovan A Argueta.;Pedro A Perez.;Chen Zhao.;Gary J Schwartz.;Nicholas V DiPatrizio.;Rebecca A Haeusler.
来源: Gut. 2020年69卷9期1620-1628页
Lipid mediators in the GI tract regulate satiation and satiety. Bile acids (BAs) regulate the absorption and metabolism of dietary lipid in the intestine, but their effects on lipid-regulated satiation and satiety are completely unknown. Investigating this is challenging because introducing excessive BAs or eliminating BAs strongly impacts GI functions. We used a mouse model (Cyp8b1-/- mice) with normal total BA levels, but alterations in the composition of the BA pool that impact multiple aspects of intestinal lipid metabolism. We tested two hypotheses: BAs affect food intake by (1) regulating production of the bioactive lipid oleoylethanolamide (OEA), which enhances satiety; or (2) regulating the quantity and localisation of hydrolysed fat in small intestine, which controls gastric emptying and satiation.
1656. Albumin in decompensated cirrhosis: new concepts and perspectives.
作者: Mauro Bernardi.;Paolo Angeli.;Joan Claria.;Richard Moreau.;Pere Gines.;Rajiv Jalan.;Paolo Caraceni.;Javier Fernandez.;Alexander L Gerbes.;Alastair J O'Brien.;Jonel Trebicka.;Thierry Thevenot.;Vicente Arroyo.
来源: Gut. 2020年69卷6期1127-1138页
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure. A further mechanism promoting multiorgan dysfunction and failure likely consists with a mitochondrial oxidative phosphorylation dysfunction responsible for systemic cellular energy crisis. The systemic proinflammatory and pro-oxidant state of patients with decompensated cirrhosis is also responsible for structural and functional changes in the albumin molecule, which spoil its pleiotropic non-oncotic properties such as antioxidant, scavenging, immune-modulating and endothelium protective functions. The knowledge of these abnormalities provides novel targets for mechanistic treatments. In this respect, the oncotic and non-oncotic properties of albumin make it a potential multitarget agent. This would expand the well-established indications to the use of albumin in decompensated cirrhosis, which mainly aim at improving effective volaemia or preventing its deterioration. Evidence has been recently provided that long-term albumin administration to patients with cirrhosis and ascites improves survival, prevents complications, eases the management of ascites and reduces hospitalisations. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration.
1658. Detection of Barrett's oesophagus through exhaled breath using an electronic nose device.
作者: Yonne Peters.;Ruud W M Schrauwen.;Adriaan C Tan.;Sanne K Bogers.;Bart de Jong.;Peter D Siersema.
来源: Gut. 2020年69卷7期1169-1172页
Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett's oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds (VOCs) analysis with an electronic nose device. This electronic nose was able to distinguish between patients with and without BO with good diagnostic accuracy (sensitivity 91% specificity 74%) and seemed to be independent of proton pump inhibitor use, the presence of hiatal hernia, and reflux. This technique may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy.
|